| pubmed-article:9014137 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9014137 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:9014137 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:9014137 | lifeskim:mentions | umls-concept:C0033004 | lld:lifeskim |
| pubmed-article:9014137 | lifeskim:mentions | umls-concept:C1709059 | lld:lifeskim |
| pubmed-article:9014137 | pubmed:issue | 9-10 | lld:pubmed |
| pubmed-article:9014137 | pubmed:dateCreated | 1997-5-12 | lld:pubmed |
| pubmed-article:9014137 | pubmed:abstractText | Utilising two point voltage-clamp techniques on Xenopus laevis oocytes expressing human (alpha 1 beta 1 gamma 2L) recombinant GABAA receptors, the GABA modulatory actions of six naturally occurring neurosteroids have been determined and compared with those of known positive allosteric modulators. The anaesthetic steroids 5 alpha- and 5 beta-pregnan-3 alpha-ol-20-one produced a concentration-dependent enhancement of the GABA-evoked current. The maximal enhancement of the agonist-induced response produced by these steroids was intermediate between that of pentobarbitone and diazepam, but much greater than that caused by bretazenil. For both the 5 alpha and 5 beta steroid a reduction of the 20 ketone group to form either the corresponding 20 alpha or 20 beta hydroxy steroid produced, in all cases, a reduction in potency and a decrease in the maximal effect. The relationship of steroid structure to these two parameters is considered. The influence of the alpha subtype (alpha x beta 1 gamma 2L, where x = 1, 2 or 3) for the behaviourally active 5 alpha-pregnan-3 alpha,20 alpha-diol is also determined. Although the maximal effect of the steroid is not influenced by the alpha subtype, the alpha 2-containing receptor exhibits a modest decrease (approximately 6-fold) in potency compared to alpha 1- and alpha 3-containing receptors. The results described here are discussed in relation to the distinct behavioural actions of the neurosteroids. | lld:pubmed |
| pubmed-article:9014137 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9014137 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9014137 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9014137 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9014137 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9014137 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9014137 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9014137 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9014137 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9014137 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9014137 | pubmed:issn | 0028-3908 | lld:pubmed |
| pubmed-article:9014137 | pubmed:author | pubmed-author:PetersJ AJA | lld:pubmed |
| pubmed-article:9014137 | pubmed:author | pubmed-author:HokK AKA | lld:pubmed |
| pubmed-article:9014137 | pubmed:author | pubmed-author:LambertJ JJJ | lld:pubmed |
| pubmed-article:9014137 | pubmed:author | pubmed-author:UkSS | lld:pubmed |
| pubmed-article:9014137 | pubmed:author | pubmed-author:BelelliDD | lld:pubmed |
| pubmed-article:9014137 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9014137 | pubmed:volume | 35 | lld:pubmed |
| pubmed-article:9014137 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9014137 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9014137 | pubmed:pagination | 1223-31 | lld:pubmed |
| pubmed-article:9014137 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:9014137 | pubmed:meshHeading | pubmed-meshheading:9014137-... | lld:pubmed |
| pubmed-article:9014137 | pubmed:meshHeading | pubmed-meshheading:9014137-... | lld:pubmed |
| pubmed-article:9014137 | pubmed:meshHeading | pubmed-meshheading:9014137-... | lld:pubmed |
| pubmed-article:9014137 | pubmed:meshHeading | pubmed-meshheading:9014137-... | lld:pubmed |
| pubmed-article:9014137 | pubmed:meshHeading | pubmed-meshheading:9014137-... | lld:pubmed |
| pubmed-article:9014137 | pubmed:meshHeading | pubmed-meshheading:9014137-... | lld:pubmed |
| pubmed-article:9014137 | pubmed:meshHeading | pubmed-meshheading:9014137-... | lld:pubmed |
| pubmed-article:9014137 | pubmed:meshHeading | pubmed-meshheading:9014137-... | lld:pubmed |
| pubmed-article:9014137 | pubmed:meshHeading | pubmed-meshheading:9014137-... | lld:pubmed |
| pubmed-article:9014137 | pubmed:meshHeading | pubmed-meshheading:9014137-... | lld:pubmed |
| pubmed-article:9014137 | pubmed:meshHeading | pubmed-meshheading:9014137-... | lld:pubmed |
| pubmed-article:9014137 | pubmed:meshHeading | pubmed-meshheading:9014137-... | lld:pubmed |
| pubmed-article:9014137 | pubmed:meshHeading | pubmed-meshheading:9014137-... | lld:pubmed |
| pubmed-article:9014137 | pubmed:meshHeading | pubmed-meshheading:9014137-... | lld:pubmed |
| pubmed-article:9014137 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:9014137 | pubmed:articleTitle | Modulation of human recombinant GABAA receptors by pregnanediols. | lld:pubmed |
| pubmed-article:9014137 | pubmed:affiliation | Department of Pharmacology and Clinical Pharmacology, Ninewells Hospital and Medical School, Dundee, U.K. | lld:pubmed |
| pubmed-article:9014137 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9014137 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9014137 | lld:pubmed |
